Pricing Log in Create free account

Nuvectis Pharma, Inc. (NVCT) vs Prime Medicine, Inc. (PRME)

Nuvectis Pharma, Inc. and Prime Medicine, Inc. are both Biotechnology companies. Nuvectis Pharma, Inc. and Prime Medicine, Inc. are of similar size ($654.8M and $618.0M). Nuvectis Pharma, Inc. has the higher net margin (0.00% vs −4,613.1%) and the higher return on invested capital (0.00% vs 0.00%). Across the 11 metrics below, Nuvectis Pharma, Inc. leads on 6 and Prime Medicine, Inc. on 5.

Valuation

Metric NVCT PRME Biotechnology median
P/E n/m n/m 8.50
P/S n/m 150.99 9.71
P/B 47.77 15.45 2.13
Price to free cash flow n/m n/m 20.82
EV/EBITDA n/m n/m 0.64
EV/Sales n/m 127.65 9.21
Earnings yield (7.09%) (30.93%) (33.15%)
Free cash flow yield (4.50%) (25.50%) (25.50%)

Profitability

Metric NVCT PRME Biotechnology median
Gross margin — 100.00% 65.16%
Operating margin 0.00% (4,824.94%) 0.00%
Net margin 0.00% (4,613.11%) 0.00%
Free cash flow margin 0.00% (3,850.92%) 0.00%
Return on equity (233.30%) (373.29%) (56.36%)
Return on assets (122.61%) (71.16%) (48.04%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric NVCT PRME Biotechnology median
Revenue growth (TTM) — (17.90%) 6.02%
EPS growth (last fiscal year) (18.92%) 18.18% 30.26%
Revenue growth, 5-year CAGR — — 9.41%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric NVCT PRME Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 1.68 3.05 4.72
Net debt to EBITDA 1.15 0.88 0.96

Dividend

Metric NVCT PRME Biotechnology median
Dividend yield — — 0.09%
Payout ratio — — —

Size

Metric NVCT PRME Biotechnology median
Market cap 617.95m 654.77m 135.18m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack